In the collaboration, Roche will elect new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL Gold technology.
The companies will collaborate on two new antibody programs in oncology. Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products.
MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than E10 million per program, plus potential royalties.
“Extending our active alliance shows a positive and constructive working relationship between Roche and MorphoSys,” said Peter Hug, Roche’s global head of Pharma Partnering. “We are pleased to collaborate with a proven partner in a new therapeutic area.”